<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869488</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3162-Ⅱ-202</org_study_id>
    <nct_id>NCT04869488</nct_id>
  </id_info>
  <brief_title>A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer</brief_title>
  <official_title>An Open, Multi-center, Phase Ⅱ Clinical Study of Fluzoparib Combined With Apatinib or Fluzoparib in the Treatment of Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort 1:&#xD;
&#xD;
      Main research purpose: To evaluate the effectiveness of fluzoparib single-drug comparison&#xD;
      researcher's choice of chemotherapy for patients with metastatic castration-resistant&#xD;
      prostate cancer;&#xD;
&#xD;
      Cohort 2, cohort 3:&#xD;
&#xD;
      Main research purpose: To evaluate the effectiveness of fluzoparil combined with apatinib&#xD;
      mesylate in the treatment of patients with metastatic castration-resistant prostate cancer;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Fluzoparib with Apatinib or Fluzoparib monotherapy in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with Abiraterone/Enzalutamine and with or without homologous recombination repair gene mutations.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: Radiological progression-free survival (rPFS) evaluated by BIRC based on the RECIST v1.1 standard and the PCWG3 standard</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2, Cohort 3: Comprehensive response rate</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological progression-free survival (rPFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>At the time point of every 8 weeks，up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>At the time point of every 4 weeks，up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At the time point of every 2 months，up to 2 year</time_frame>
    <description>Number of Participants with Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Fluzoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzoparib Combined With Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Fluzoparib Orally twice daily（Cohort 1）</description>
    <arm_group_label>Fluzoparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets</intervention_name>
    <description>Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）</description>
    <arm_group_label>Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib Combined With Apatinib</intervention_name>
    <description>Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3）</description>
    <arm_group_label>Fluzoparib Combined With Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary participation and written informed consent;&#xD;
&#xD;
          2. Age ≥18 years old&#xD;
&#xD;
          3. Pathologically diagnosed metastatic castration-resistant prostate adenocarcinoma&#xD;
&#xD;
          4. It is confirmed by the central laboratory based on tumor tissue or ctDNA detection&#xD;
             that it is accompanied by germline or system homologous recombination repair-related&#xD;
             gene mutations (Cohorts 1 and 3) or not accompanied by homologous recombination&#xD;
             repair-related gene mutations (Cohort 2)&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          6. Has a life expectancy of ≥ 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past (within 5 years) or concurrently suffering from other malignant tumors, except&#xD;
             for cured skin basal cell carcinoma&#xD;
&#xD;
          2. Subjects have used PARP inhibitors in the past, including but not limited to olaparib,&#xD;
             niraparib, and lukapanib; or have used apatinib in the past; or have received&#xD;
             mitoxantrone and cyclophosphine in the past Treatment with amide or&#xD;
             platinum-containing chemotherapeutics&#xD;
&#xD;
          3. Severe bone injury caused by tumor bone metastasis, pathological fractures or spinal&#xD;
             cord compression in important parts that occurred within 6 months before being&#xD;
             informed or is expected to occur in the near future&#xD;
&#xD;
          4. The subject has cancerous meningitis, or untreated central nervous system metastasis&#xD;
&#xD;
          5. Those who cannot swallow pills normally, or have abnormal gastrointestinal function,&#xD;
             which may affect drug absorption by the researcher&#xD;
&#xD;
          6. Subjects with congenital or acquired immune deficiencies (such as HIV infection), or&#xD;
             active hepatitis (hepatitis B reference: HBsAg positive and HBV DNA ≥500 IU/ml;&#xD;
             hepatitis C reference: HCV antibody positive and HCV virus copy number&gt; upper limit of&#xD;
             normal )&#xD;
&#xD;
          7. According to the judgment of the investigator, the subject has other factors that may&#xD;
             cause the study to be terminated halfway, such as other serious diseases (including&#xD;
             mental illness) that require combined treatment, severe laboratory abnormalities,&#xD;
             family or society, etc. Factors that will affect the safety of subjects or the&#xD;
             collection of data and samples&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quanren Wang</last_name>
    <phone>18036618570</phone>
    <email>wangquanren@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peng Xiu</last_name>
    <phone>17721286339</phone>
    <email>peng.xiu@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

